252 related articles for article (PubMed ID: 18671247)
1. Genetic aberrations of gastrointestinal stromal tumors.
Yang J; Du X; Lazar AJ; Pollock R; Hunt K; Chen K; Hao X; Trent J; Zhang W
Cancer; 2008 Oct; 113(7):1532-43. PubMed ID: 18671247
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.
Yamamoto H; Tobo T; Nakamori M; Imamura M; Kojima A; Oda Y; Nakamura N; Takahira T; Yao T; Tsuneyoshi M
J Cancer Res Clin Oncol; 2009 Jun; 135(6):791-8. PubMed ID: 19020900
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors.
Schaefer IM; Delfs C; Cameron S; Gunawan B; Agaimy A; Ghadimi BM; Haller F
Hum Pathol; 2014 Jan; 45(1):85-97. PubMed ID: 24157063
[TBL] [Abstract][Full Text] [Related]
4. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
5. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
[TBL] [Abstract][Full Text] [Related]
6. Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status.
Wozniak A; Sciot R; Guillou L; Pauwels P; Wasag B; Stul M; Vermeesch JR; Vandenberghe P; Limon J; Debiec-Rychter M
Genes Chromosomes Cancer; 2007 Mar; 46(3):261-76. PubMed ID: 17171690
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of an Italian series of sporadic GISTs.
Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
9. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
[No Abstract] [Full Text] [Related]
10. Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behaviour.
Schaefer IM; Ströbel P; Cameron S; Beham A; Otto C; Schildhaus HU; Agaimy A
Histopathology; 2014 Feb; 64(3):421-30. PubMed ID: 24266839
[TBL] [Abstract][Full Text] [Related]
11. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
Miettinen M; Lasota J
Arch Pathol Lab Med; 2006 Oct; 130(10):1466-78. PubMed ID: 17090188
[TBL] [Abstract][Full Text] [Related]
14. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
15. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.
Belinsky MG; Skorobogatko YV; Rink L; Pei J; Cai KQ; Vanderveer LA; Riddell D; Merkel E; Tarn C; Eisenberg BL; von Mehren M; Testa JR; Godwin AK
Genes Chromosomes Cancer; 2009 Oct; 48(10):886-96. PubMed ID: 19585585
[TBL] [Abstract][Full Text] [Related]
16. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
17. Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors.
Silva M; Veiga I; Ribeiro FR; Vieira J; Pinto C; Pinheiro M; Mesquita B; Santos C; Soares M; Dinis J; Santos L; Lopes P; Afonso M; Lopes C; Teixeira MR
BMC Med; 2010 May; 8():26. PubMed ID: 20470368
[TBL] [Abstract][Full Text] [Related]
18. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
